High-resolution melt analysis to detect sequence variations in highly homologous gene regions: Application to CYP2B6

Pharmacogenomics

Volumn 14, Issue 8, 2013, Pages 913-922

  Twist, Greyson P ^a   Gaedigk, Roger ^a   Steven Leeder, J ^a   Gaedigk, Andrea ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

CYP2B6; CYP2B7; genotyping; high resolution melt analysis; HRM; SNPs

Indexed keywords

CYTOCHROME P450 2B6; GENOMIC DNA;

AFRICAN AMERICAN; AMPLICON; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CYP2B6 GENE; CYP2B7 GENE; EXON; GENOTYPE; HAPLOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PSEUDOGENE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC VARIATION; GENOTYPE; GENOTYPING TECHNIQUES; HAPLOTYPES; HUMANS; LIVER; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSITION TEMPERATURE;

EID: 84878869497     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.66     Document Type: Article

References (41)

1. Vossen RH, Aten E, Roos A, Den Dunnen JT. High-resolution melting analysis (HRMA): more than just sequence variant screening. Hum. Mutat. 30(6), 860-866 (2009).
2. Tong SY, Giffard PM. Microbiological applications of high-resolution melting analysis. J. Clin. Microbiol. 50(11), 3418-3421 (2012).
3. Bester R, Jooste AE, Maree HJ, Burger JT. Real-time RT-PCR high resolution melting curve analysis and multiplex RT-PCR to detect and differentiate grapevine leafroll-associated associated virus 3 variant groups I, II, III and VI. Virol. J. 9(1), 219 (2012).
4. Cousins MM, Ou SS, Wawer MJ et al. Comparison of a high-resolution melting assay to next-generation sequencing for analysis of HIV diversity. J. Clin. Microbiol. 50(9), 3054-3059 (2012).
5. Tindall EA, Petersen DC, Woodbridge P, Schipany K, Hayes VM. Assessing high-resolution melt curve analysis for accurate detection of gene variants in complex DNA fragments. Hum. Mutat. 30(6), 876-883 (2009).
6. Dobrowolski SF, Gray J, Miller T, Sears M. Identifying sequence variants in the human mitochondrial genome using high-resolution melt (HRM) profiling. Hum. Mutat. 30(6), 891-898 (2009).
7. Lundgren A, Kim S, Stadnisky MD, Brown MG. Rapid discrimination of MHC class I and killer cell lectin-like receptor allele variants by high-resolution melt analysis. Immunogenetics 64(8), 633-640 (2012).
8. Er TK, Chang JG. High-resolution melting: applications in genetic disorders. Clin. Chim. Acta 414C, 197-201 (2012).
9. van der Stoep N, van Paridon CDM, Janssens T et al. Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner(tm). Hum. Mutat. 30(6), 899-909 (2009).
10. Gonzalez-Bosquet J, Calcei J, Wei JS et al. Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers. PLoS ONE 6(1), e14522 (2011).
11. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6 ): advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet. 4, 24 (2013).
12. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8(7), 743-759 (2007). (Pubitemid 47288975)
13. Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14(4), 225-238 (2004). (Pubitemid 38530514)
14. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450-reductase complex. J. Pharmacol. Exp. Ther. 338(3), 803-809 (2011).
15. Kirchheiner J, Klein C, Meineke I et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13(10), 619-626 (2003). (Pubitemid 37311148)
16. Desta Z, Saussele T, Ward B et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8(6), 547-558 (2007). (Pubitemid 46947859)
17. Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81(4), 557-566 (2007). (Pubitemid 46454205)
18. Mutwa PR, Fillekes Q, Malgaz M et al. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms. J. Acquir. Immune Defic. Syndr. 60(4), 400-404 (2012).
19. Li J, Menard V, Benish RL et al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics 13(5), 555-570 (2012).
20. Kansaku F, Kumai T, Sasaki K et al. Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age. Drug Metab. Pharmacokinet. 26(5), 532-537 (2011).
21. Murayama N, Minoshima M, Shimizu M, Guengerich FP, Yamazaki H. Involvement of human cytochrome P450 2B6 in the w-and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica 37(7), 717-724 (2007). (Pubitemid 47057122)
22. Dobrinas M, Crettol S, Oneda B et al. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenet. Genomics 23(2), 84-93 (2013).
23. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet. Genomics 18(6), 515-523 (2008). (Pubitemid 351769919)
24. Tran A, Bournerias F, Le Beller C et al. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. Br. J. Clin. Pharmacol. 65(2), 279-280 (2008). (Pubitemid 351171274)
25. Helsby NA, Hui CY, Goldthorpe MA et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br. J. Clin. Pharmacol. 70(6), 844-853 (2010).
26. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 9(7), 598-610 (2008).
27. Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, Zhou SF. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr. Drug Metab. 10(7), 730-753 (2009).
28. Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet. Genomics 20(8), 520-523 (2010).
29. Helsby N, Tingle M. The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status. Am. J. Hematol. 86(4), 383-384; author reply 384 (2011).
30. Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11(5), 399-415 (2001). (Pubitemid 32656581)
31. Jacob RM, Johnstone EC, Neville MJ, Walton RT. Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. Clin. Chem. 50(8), 1372-1377 (2004). (Pubitemid 38970644)
32. Blievernicht JK, Schaeffeler E, Klein K, Eichelbaum M, Schwab M, Zanger UM. MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms. Clin. Chem. 53(1), 24-33 (2007). (Pubitemid 46047760)
33. Black JL, Litzow MR, Hogan WJ et al. Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. Leukemia Res. 36(1), 59-66 (2012).
34. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003). (Pubitemid 37414228)
35. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001). (Pubitemid 32289743)
36. Chang CC, Lin PC, Lin CH, Yeh KT, Hung HY, Chang JG. Rapid identification of CYP2C8 polymorphisms by high resolution melting analysis. Clin. Chim. Acta 413(1-2), 298-302 (2012).
37. Temesvari M, Paulik J, Kobori L, Monostory K. High-resolution melting curve analysis to establish CYP2C19 2 single nucleotide polymorphism: comparison with hydrolysis SNP analysis. Mol. Cell Probes 25(2-3), 130-133 (2011).
38. Pindurova E, Zourkova A, Zrustova J, Jurica J, Pavelka A. Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping. Mol. Biotechnol. 53(1), 29-40 (2013).
39. Lin YC, Liu TC, Chang JG, Lee HH. High-resolution melting curve (HRM) analysis to establish CYP21A2 mutations converted from the CYP21A1P in congenital adrenal hyperplasia. Clin. Chim. Acta 412(21-22), 1918-1923 (2011).
40. Seipp MT, Durtschi JD, Liew MA et al. Unlabeled oligonucleotides as internal temperature controls for genotyping by amplicon melting. J. Mol. Diagn. 9(3), 284-289 (2007). (Pubitemid 47305063)
41. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics 13(1), 91-111 (2012).